Real‐World Effectiveness of Switching to Oral or Infusion Versus Injectable Disease‐Modifying Therapy in Pediatric Multiple Sclerosis
Annals of Neurology · 2025
DOI: 10.1002/ana.78086 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Neurology, 2025. Verfasst von Aaron W Abrams und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Cleveland Clinic, Cleveland, OH. Hauptthemen laut MEDLINE: Multiple Sclerosis, Immunologic Factors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Multiple Sclerosis Society.
Abstract (Originalsprache)
Objective
To assess real‐world effectiveness of switching disease‐modifying therapy (DMT) in pediatric multiple sclerosis (MS) and clinically isolated syndrome (CIS) initially treated with platform injectables on disease activity.
Methods
Of 2615 pediatric‐onset demyelinating disease patients at 12 clinics in the United States (US) Network of Pediatric MS Centers, those with MS/CIS on initial therapy with a platform injectable who switched to another class of platform injectable, oral or infusion DMT were analyzed. Relapse rate was modeled with negative binomial regression, adjusted for preidentified confounders.
Results
A total of 212 children switched DMT before age 18 (67% female, 95% MS). Ninety‐three switched from injectable to injectable, 76 injectable to oral, and 43 injectable to infusion. Switchers to oral or infusion were older at onset (injectable 12.3 years, oral 13.5 years, and infusion 14.2 years) and switch (injectable 14.6 years, oral 16.0 years, and infusion 15.7 years). Switchers to infusion DMT were more likely to have enhancing lesions (injectable 45%, oral 28%, and infusion 67%). Compared to injectable (annualized relapse rate [ARR] = 0.88, 95% confidence interval [CI] = 0.52–1.48), relapse rates were lower for injectable to oral (ARR = 0.34, 95% CI = 0.20–0.57; rate ratio: 0.38, 95% CI = 0.21–0.69) and injectable to infusion (ARR = 0.18, 95% CI = 0.09–0.37; rate ratio: 0.21, 95% CI = 0.10–0.44) ( p < 0.001). Adjusted number needed to treat in person‐years to prevent 1 relapse with oral over injectable was 1.84 (95% CI = 1.03–8.69) and infusion over injectable 1.43 (95% CI = 1.00–3.88).
Interpretation
Switching from platform injectable to oral or infusion compared to other platform injectable DMT led to better disease control in pediatric MS. Long‐term safety data are required. ANN NEUROL 2025
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Cleveland Clinic, Cleveland, OH.
- Department of Pediatrics, University of Utah, Salt Lake City, UT.
- Department of Pediatrics, Loma Linda University, San Bernardino, CA.
- Department of Neurology, Boston Children's Hospital, Boston, MA.
- Department of Neurology, New York University Langone Health, New York, NY.
- Department of Pediatric Neurology, Massachusetts General Hospital, Boston, MA.
ORCID-Profile: Aaron W Abrams, Leigh E Charvet, Lauren Krupp, Kimberly O'Neill, Emmanuelle Waubant, Kristen M Krysko
Förderung
- National Multiple Sclerosis Society
Zitieren
APA
Abrams, A. W., Waltz, M., Casper, T. C., Aaen, G., Benson, L. A., Bernfeld, E. M., Charvet, L. E., Chitnis, T., Francisco, C., Gorman, M. P., Graves, J. S., Krupp, L., O'Neill, K., Lotze, T. E., Mar, S., Ness, J., Rensel, M., Rodriguez, M., Rose, J., …, & US Network of Pediatric MS Centers (2025). Real‐World Effectiveness of Switching to Oral or Infusion Versus Injectable Disease‐Modifying Therapy in Pediatric Multiple Sclerosis. Annals of Neurology. https://doi.org/10.1002/ana.78086
Vancouver
Abrams AW, Waltz M, Casper TC, Aaen G, Benson LA, Bernfeld EM, et al. Real‐World Effectiveness of Switching to Oral or Infusion Versus Injectable Disease‐Modifying Therapy in Pediatric Multiple Sclerosis. Annals of Neurology. 2025. doi:10.1002/ana.78086
BibTeX
@article{Abrams2025,
author = {Abrams, Aaron W and Waltz, Michael and Casper, T Charles and Aaen, Gregory and Benson, Leslie A and Bernfeld, Eva-Chava M and Charvet, Leigh E and Chitnis, Tanuja and Francisco, Carla and Gorman, Mark P and Graves, Jennifer S and Krupp, Lauren and O'Neill, Kimberly and Lotze, Timothy E and Mar, Soe and Ness, Jayne and Rensel, Mary and Rodriguez, Moses and Rose, John and Rutatangwa, Alice and Schreiner, Teri and Shukla, Nikita and Tillema, Jan-Mendelt and Weinstock-Guttman, Bianca and Wheeler, Yolanda and Waubant, Emmanuelle and Krysko, Kristen M and US Network of Pediatric MS Centers, US Network of Pediatric MS Centers},
title = {Real‐World Effectiveness of Switching to Oral or Infusion Versus Injectable Disease‐Modifying Therapy in Pediatric Multiple Sclerosis},
journal = {Annals of Neurology},
year = {2025},
doi = {10.1002/ana.78086}
}
EUVIMED